Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that Business 2.0 has published an article about Nutra Pharma and its scientific research using snake venom in drug discovery.
“It is an honor for Nutra Pharma to be spotlighted in the July issue of Business 2.0,” explained Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corp. “This is one of the leading and most popular business magazines and this article will provide incredible exposure for the company and its breakthrough scientific research,” he concluded.
The article, entitled “Betting on Bites”, is available in the July 2006 issue of Business 2.0.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The publication of the Business 2.0 article about Nutra Pharma should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.